Your about to leave the site and are being redirected to another site. Would you like to leave this site?

Image-1

Image-1

INDICATION

BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who:
  • Have disease progression during or following platinum-containing chemotherapy
  • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

 

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Visit CoverOne.com to learn about patient access and reimbursement support for BAVENCIO—or call 844-8COVER1
(844-826-8371).

PRODUCT INFORMATION SHEET